Recombinant Human RCVRN protein, His&Myc-tagged

• Cat.No.: RCVRN-5057H
• Product Overview: Recombinant Human RCVRN protein(P35243)(2-200aa), fused to N-terminal His tag and C-terminal Myc tag, was expressed in HEK293.

Specification

• Source: HEK293
• Species: Human
• Tag: His&Myc
• Form: If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
  If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
• Molecular Mass: 27.0 kDa
• Protein length: 2-200aa
• Purity: Greater than 90% as determined by SDS-PAGE.
• Storage: Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
• Reconstitution: Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%.

Gene Information

• Gene Name: RCVRN recoverin [ Homo sapiens ]
• Official Symbol: RCVRN
• Synonyms: RCVRN; recoverin; RCV1; cancer associated retinopathy antigen; cancer-associated retinopathy protein
• Gene ID: 5957
• mRNA Refseq: NM_002903
• Protein Refseq: NP_002894
• MIM: 179618
• UniProt ID: P35243

Reviews

02/16/2020

Whether investigating metabolic pathways, studying enzymatic activity, or exploring drug targets, this protein offers versatility and reliability, allowing for accurate and meaningful data collection.

05/29/2018

In addition to the remarkable protein quality, the manufacturer provides excellent technical support, proving to be a valuable resource when troubleshooting experimental challenges.

06/24/2016

Incorporating this protein into scientific investigations undoubtedly enhances the reliability and effectiveness of research endeavors.

Q&As

Are there any specific populations that may benefit more from RCVRN-targeted therapies?

Individuals with genetic mutations affecting RCVRN and those with early-stage retinal diseases may potentially benefit more from targeted therapies.

How does the expression of RCVRN change with age, and does this have implications for age-related vision disorders?

The expression of RCVRN may change with age, and understanding these changes can provide insights into age-related vision disorders.

How is the level of RCVRN expression correlated with the progression of certain retinal disorders?

Changes in RCVRN expression levels may correlate with the progression of retinal disorders, serving as a potential indicator of disease severity.

Are there ongoing clinical trials exploring the use of RCVRN-based therapies?

Some clinical trials are investigating the safety and efficacy of gene therapies targeting the RCVRN gene for treating specific eye conditions.

How might the manipulation of RCVRN expression offer therapeutic benefits for patients with vision impairments?

Modulating RCVRN expression could potentially restore or enhance photoreceptor function, providing therapeutic benefits for vision-impaired individuals.